Meet the 10th cohort for gBETA Houston. Photo via gener8tor.com

National venture capital firm gener8tor named its 10th Houston cohort this week, which includes startups focused on innovative tableware to substitute teacher operations.

gBETA Houston offers startups and founders with a non-equity seven-week program that features intensive concierge coaching and access to a network of investors and partners. The founders will pitch their ideas on Oct. 24 at 6:30 p.m. at the Esperson Building.

"Each cohort shows us how innovation evolves and thrives," Muriel Foster, gBETA Houston director, says in a statement. "The Spring 2024 gBETA Houston cohort embodies creative brilliance and unyielding ambition."

The five companies named to gBETA were chosen based on their growth potential and investor readiness. They include:

  • BrainBuffet, an AI-powered platform that has already created over 250 courses to refine its personalized learning algorithm that builds customized courses that feature curated content, YouTube videos, quizzes, and progress tracking
  • Colorfull Plates, a tableware startup that creates durable, vibrant products that aim to streamline family meals and encourage children to try new flavors. It has generated $300,000 in revenue without outside dilutive funding.
  • The Parent Teacher Collaborative, a web- and mobile-based platform that aims to improve student outcomes by building strong collaborative partnerships, growing parent-teacher organizations and better managing school events. It's worked with five Houston-area communities and has raised over $144,000 in grant and contract funding since April 2023.
  • Kinfolk, a user-friendly mobile application that creates a digital time capsule of family traditions, memories and cultural heritage. It has over 50 beta-testing customers.
  • SubSpark, a mobile and desktop app that allows school administrators and teachers to post available openings for substitute teachers. The Houston-based LLC is currently beta-testing its apps with one Houston-area private school.

The five companies joined the spring 2024 cohort and the rest of the Houston gBETA network.

gBETA is supported by Downtown Houston, the City of Houston and the Downtown Redevelopment Authority. The program has accelerated 45 Houston companies since its launch in Houston in 2019. It was launched by a $1.25 million grant to be paid out over five years.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.